Cargando…

Treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real‐world study

INTRODUCTION: Anti‐vascular endothelial growth factors (anti‐VEGFs) are considered standard of care therapy for diabetic macular oedema (DME). This study examined treatment patterns and outcomes in patients with DME treated with anti‐VEGF therapy. METHODS: Using anonymized electronic medical record...

Descripción completa

Detalles Bibliográficos
Autores principales: Peto, Tunde, Akerele, Toks, Sagkriotis, Alexandros, Zappacosta, Sofia, Clemens, Andreas, Chakravarthy, Usha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299692/
https://www.ncbi.nlm.nih.gov/pubmed/34796985
http://dx.doi.org/10.1111/dme.14746
_version_ 1784751033668337664
author Peto, Tunde
Akerele, Toks
Sagkriotis, Alexandros
Zappacosta, Sofia
Clemens, Andreas
Chakravarthy, Usha
author_facet Peto, Tunde
Akerele, Toks
Sagkriotis, Alexandros
Zappacosta, Sofia
Clemens, Andreas
Chakravarthy, Usha
author_sort Peto, Tunde
collection PubMed
description INTRODUCTION: Anti‐vascular endothelial growth factors (anti‐VEGFs) are considered standard of care therapy for diabetic macular oedema (DME). This study examined treatment patterns and outcomes in patients with DME treated with anti‐VEGF therapy. METHODS: Using anonymized electronic medical record data collected from three UK sites, this retrospective cohort study assessed rates of anti‐VEGF intravitreal injections in adults with treatment‐naïve DME who received their first treatment between 1 September 2010 and 31 July 2018. The proportion of patients with at least one interval of at least 12 weeks between injections; the distribution of injection intervals; the discontinuation rates; and the number of anti‐VEGF injection‐, injection‐free‐ and total visits were assessed during the first and second years of treatment. RESULTS: Overall, 1606 patient eyes with DME were included, with no minimum follow‐up. During the first and second year of treatment, 63.2% and 73.1% of eyes had at least one anti‐VEGF injection interval of at least 12 weeks, respectively. In the first and second years of treatment, the mean (standard deviation) numbers of injections were 7.7 (1.9) and 5.6 (2.2), with 14.2 (5.7) and 13.4 (6.4) total clinic visits, and 6.6 (5.0) and 7.8 (5.8) injection‐free visits, respectively. In total, 27.8% of patient eyes discontinued treatment during the first 2 years. CONCLUSIONS: The high number of clinic visits and high discontinuation rates demonstrate a significant unmet need for a treatment to enable sustainable extended injection intervals, while maintaining visual acuity. This could improve patient adherence and health‐related quality of life for patients with DME.
format Online
Article
Text
id pubmed-9299692
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92996922022-07-21 Treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real‐world study Peto, Tunde Akerele, Toks Sagkriotis, Alexandros Zappacosta, Sofia Clemens, Andreas Chakravarthy, Usha Diabet Med Research: Complications INTRODUCTION: Anti‐vascular endothelial growth factors (anti‐VEGFs) are considered standard of care therapy for diabetic macular oedema (DME). This study examined treatment patterns and outcomes in patients with DME treated with anti‐VEGF therapy. METHODS: Using anonymized electronic medical record data collected from three UK sites, this retrospective cohort study assessed rates of anti‐VEGF intravitreal injections in adults with treatment‐naïve DME who received their first treatment between 1 September 2010 and 31 July 2018. The proportion of patients with at least one interval of at least 12 weeks between injections; the distribution of injection intervals; the discontinuation rates; and the number of anti‐VEGF injection‐, injection‐free‐ and total visits were assessed during the first and second years of treatment. RESULTS: Overall, 1606 patient eyes with DME were included, with no minimum follow‐up. During the first and second year of treatment, 63.2% and 73.1% of eyes had at least one anti‐VEGF injection interval of at least 12 weeks, respectively. In the first and second years of treatment, the mean (standard deviation) numbers of injections were 7.7 (1.9) and 5.6 (2.2), with 14.2 (5.7) and 13.4 (6.4) total clinic visits, and 6.6 (5.0) and 7.8 (5.8) injection‐free visits, respectively. In total, 27.8% of patient eyes discontinued treatment during the first 2 years. CONCLUSIONS: The high number of clinic visits and high discontinuation rates demonstrate a significant unmet need for a treatment to enable sustainable extended injection intervals, while maintaining visual acuity. This could improve patient adherence and health‐related quality of life for patients with DME. John Wiley and Sons Inc. 2021-12-15 2022-04 /pmc/articles/PMC9299692/ /pubmed/34796985 http://dx.doi.org/10.1111/dme.14746 Text en © 2021 Novartis Pharma AG. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research: Complications
Peto, Tunde
Akerele, Toks
Sagkriotis, Alexandros
Zappacosta, Sofia
Clemens, Andreas
Chakravarthy, Usha
Treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real‐world study
title Treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real‐world study
title_full Treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real‐world study
title_fullStr Treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real‐world study
title_full_unstemmed Treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real‐world study
title_short Treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real‐world study
title_sort treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the uk: a real‐world study
topic Research: Complications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299692/
https://www.ncbi.nlm.nih.gov/pubmed/34796985
http://dx.doi.org/10.1111/dme.14746
work_keys_str_mv AT petotunde treatmentpatternsandpersistencerateswithantivascularendothelialgrowthfactortreatmentfordiabeticmacularoedemaintheukarealworldstudy
AT akereletoks treatmentpatternsandpersistencerateswithantivascularendothelialgrowthfactortreatmentfordiabeticmacularoedemaintheukarealworldstudy
AT sagkriotisalexandros treatmentpatternsandpersistencerateswithantivascularendothelialgrowthfactortreatmentfordiabeticmacularoedemaintheukarealworldstudy
AT zappacostasofia treatmentpatternsandpersistencerateswithantivascularendothelialgrowthfactortreatmentfordiabeticmacularoedemaintheukarealworldstudy
AT clemensandreas treatmentpatternsandpersistencerateswithantivascularendothelialgrowthfactortreatmentfordiabeticmacularoedemaintheukarealworldstudy
AT chakravarthyusha treatmentpatternsandpersistencerateswithantivascularendothelialgrowthfactortreatmentfordiabeticmacularoedemaintheukarealworldstudy